Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined
with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who
are not adolescents or patients with new, progressive brain metastasis will be stratified by
PD-L1 expression and LDH level.